Hemab
Jørgen Søberg Petersen, MD, PhD, DMSc, MBA, is Hemab’s immediate Past Board Chair. Dr. Pedersen trained in medicine in Denmark and in the United States. During his 20 years in the pharmaceutical industry, he served in executive R&D roles at Lundbeck, Zealand Pharma, Merck, and Novo Nordisk. He co-founded Zealand Pharma and built the company to exit. He has extensive experience in rare disease development and financing of rare disease companies and is currently a Partner at Novo Holdings. He earned an MD, PhD in Pharmacology, and DMSc from the University of Copenhagen, Denmark, and an MBA from the Technical University of Denmark.
This person is not in the org chart
This person is not in any teams
Hemab
Hemab Therapeutics ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.